| Literature DB >> 23526945 |
Gonzalo Durante-Rodríguez1, José Miguel Mancheño, Germán Rivas, Carlos Alfonso, José Luis García, Eduardo Díaz, Manuel Carmona.
Abstract
The evolution of transcriptional regulators through the recruitment of DNA-binding domains by enzymes is a widely held notion. However, few experimental approaches have directly addressed this hypothesis. Here we report the reconstruction of a plausible pathway for the evolution of an enzyme into a transcriptional regulator. The BzdR protein is the prototype of a subfamily of prokaryotic transcriptional regulators that controls the expression of genes involved in the anaerobic degradation of benzoate. We have shown that BzdR consists of an N-terminal DNA-binding domain connected through a linker to a C-terminal effector-binding domain that shows significant identity to the shikimate kinase (SK). The construction of active synthetic BzdR-like regulators by fusing the DNA-binding domain of BzdR to the Escherichia coli SKI protein strongly supports the notion that an ancestral SK domain could have been involved in the evolutionary origin of BzdR. The loss of the enzymatic activity of the ancestral SK domain was essential for it to evolve as a regulatory domain in the current BzdR protein. This work also supports the view that enzymes precede the emergence of the regulatory systems that may control their expression.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23526945 PMCID: PMC3602430 DOI: 10.1371/journal.pone.0057518
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Figure 1Modular architecture of the BzdR derivatives.
Diagram showing the modular architecture of the BzdR protein, its NBzdR, NBzdRL and CBzdR domains, and the Q1, Q2 and Q1ΔL chimeras. The N-terminal domain (NBzdR), C-terminal domain (CBzdR) and linker region of BzdR are indicated in orange, blue and green, respectively. The E. coli SKI enzyme is shown in violet, and the Asp168Ala substitution in the Q2 chimera is indicated by an asterisk in red.
Bacterial strains and plasmids used in this work.
| Strain or plasmid | Relevant phenotype and/or genotypea | Reference |
|
| ||
| DH5α |
|
|
| M15 | Strain for regulated high level expression with pQE vectors | Qiagen |
| MC4100 | F−, |
|
| AFMC | MC4100 spontaneous Rfr |
|
| AFMCPN | Rfr, Kmr, AFMC harbouring |
|
| ALO807 | F−, |
|
| CC118 | Rfr, Spr, Δ( |
|
| Plasmids | ||
| pQE32 | Apr, | Qiagen |
| pQE32-His6BzdR | Apr, pQE32 derivative harboring the His6- |
|
| pQE32-His6NBzdR | Apr, pQE32 derivative harboring the His6- | This work |
| pQE32-His6NBzdRL | Apr, pQE32 derivative harboring the His6- | This work |
| pQE32-His6CBzdR | Apr, pQE32 derivative harboring the His6- | This work |
| pQE32-His6Q1 | Apr, pQE32 derivative harboring the His6- | This work |
| pQE32-His6Q2 | Apr, pQE32 derivative harboring the His6- | This work |
| pQE32-His6Q1ΔL | Apr, pQE32 derivative harboring the His6- | This work |
| pQE32-His6SKI | Apr, pQE32 derivative harboring the His6- | This work |
| pJCD-PN | Apr, pJCD01 derivative harboring a 585-bp |
|
| pQE60-His6-FNR* | Apr, pQE60 derivative that harbors the His6- |
|
| pREP4 | Kmr, plasmid that expresses the | Qiagen |
| pECOR7 | Apr, pUC19 harboring a 7.1-kb DNA fragment containing the |
|
| pGEM-Teasy | Apr, | Promega |
| pGEMT-NBzdRL | Apr, pGEM-Teasy derivative harboring the | This work |
| pGEMT-NBzdR | Apr, pGEM-Teasy derivative harboring the | This work |
| pGEMT-CBzdR | Apr, pGEM-Teasy derivative harboring the | This work |
| pGEMT-SKI | Apr, pGEM-Teasy derivative harboring the | This work |
| pGEMT-Q1 | Apr, pGEM-Teasy derivative harboring the | This work |
| pCK01 | Cmr, |
|
| pCK01BzdR | Cmr, pCK01 derivative harboring a DNA fragment containing the |
|
| pCK01Q1 | Cmr, pCK01 derivative harboring the | This work |
| pCK01Q2 | Cmr, pCK01 derivative harboring the | This work |
| pCK01NBzdR | Cmr, pCK01 derivative harboring the | This work |
| pCK01NBzdRL | Cmr, pCK01 derivative harboring the | This work |
| pSJ3PN | Apr, pSJ3 derivative harbouring the translational fusion |
|
Apr, ampicillin resistant; Cmr chloramphenicol resistant; Kmr, kanamycin resistant; Nalr, nalidixic acid; Rfr, rifampicin resistant; Smr, streptomycin resistant; Spr, spectinomycin resistant.
Figure 2The N-terminal domain of BzdR is a functional DNA-binding domain.
A. DNase I footprinting experiments were performed using the P probe and the purified regulators His6-BzdR (control), His6-NBzdR, and His6-NBzdRL. The figure shows the results of footprinting assays conducted in the absence of the regulators (lane C), or the presence of 50, 100, or 200 nM of His6-NBzdR (lanes 1 to 3, respectively) or His6-NBzdRL (lanes 4 to 6, respectively). Lanes 7 and 8 are footprinting assays containing 50 and 100 nM of purified His6-BzdR. Lane AG shows the A+G Maxam and Gilbert sequencing reaction. Protected regions (I, II, and III) are indicated with brackets. The −10 box and the transcription initiation site (+1) of the P promoter are also shown. Phosphodiester bonds hypersensitive to DNase I cleavage are indicated by asterisks. B. In vivo effect of the N-terminal domain of BzdR on the repression of the P promoter. E. coli AFMCPN cells (containing a P fusion chromosome insertion of the) harboring plasmid pCK01BzdR (BzdR), pCK01NBzdR (NBzdR) or pCK01NBzdRL (NBzdRL) or the control plasmid pCK01 (-), were grown anaerobically in LB medium until the mid-exponential culture phase. β-galactosidase activity is expressed in Miller units. Results from three independent experiments (n = 3) and errors bars are shown. C. Effect of BzdR, NBzdR and NBzdRL on in vitro transcription from P. Multiple-round in vitro transcription reactions were performed using the pJCD-PN plasmid template, which produces a 184-nt mRNA from P (arrow), 50 nM E. coli RNAP, and 20 nM Fnr* activator. Transcription reactions were carried out in the absence of repressor (lane -) or presence of 40 nM purified His6-BzdR (lanes BzdR), His6-NBzdR (lanes NBzdR) or His6-NBzdRL (lanes NBzdRL) and in the absence (-) or presence (+) of 2 mM benzoyl-CoA.
Figure 3In vitro and in vivo effects of the Q1, Q1ΔL and Q2 chimeras on the P promoter.
(A) DNase I footprinting experiments performed out using the P probe and the purified regulators His6-BzdR (control) and His6-Q1. The figure shows the results of footprinting assays conducted in the absence of the regulators (lane C), or presence of 25, 50, 100, and 200 nM of His6-BzdR (lanes 1 to 4, respectively) or His6-Q1 (lanes 5 to 8, respectively). Lane AG shows the A+G Maxam and Gilbert sequencing reaction. Protected regions (I, II, and III) are indicated by brackets. The -10 box and the transcription initiation site (+1) of the P promoter are also shown. Phosphodiester bonds hypersensitive to DNase I cleavage are indicated by asterisks. (B) In vitro effect of the Q1 and Q1ΔL chimeras on the activity of P. Multiple-round in vitro transcription reactions were performed using the pJCD-PN plasmid template, which produces a 184-nt mRNA from P (arrow), 50 nM E. coli RNA polymerase (RNAP), and 20 nM Fnr* activator [12]. Transcription reactions were conducted in the absence of chimeric regulator (lane 1) or presence of 25 nM (lane 2) or 50 nM (lanes 3–12) of purified His6-Q1 or His6-Q1ΔL proteins. Shikimate (S) or shikimate plus ATP (S+ATP) were added at 1 mM (lanes 4 and 7), 2 mM (lanes 5 and 8) or 4 mM (lanes 6, 9, 11 and 12). (C) In vivo effect of BzdR (control) and the Q1 and Q2 chimeras on the activity of the P promoter. β-galactosidase activity (in Miller units) of E. coli MC4100 cells harboring plasmid pSJ3PN (P) and the plasmids pCK01BzdR (BzdR), pCK01Q1 (Q1), pCK01Q2 (Q2), or the control plasmid pCK01 (-). Cells were grown anaerobically until mid-exponential phase in LB medium supplemented, when indicated, with 5 mM shikimate (S). Results from three independent experiments (n = 3) and errors bars are shown. (D). In vitro effect of the Q2 chimera on the activity of P. In vitro transcription reactions were performed as in panel B, in the absence of Q2 (lane 1) or presence of 25 nM (lane 2) or 50 nM (lanes 3–9) of purified His6-Q2 protein. Shikimate (S) or shikimate plus ATP (S+ATP) were added at 1 mM (lanes 4 and 7), 2 mM (lanes 5 and 8) or 4 mM (lanes 6 and 9).
Figure 4Effect of different ligands on BzdR-, Q1- or Q2-mediated repression of P.
In vitro transcription reactions were run as in Figure 2B, in the absence of repressor proteins (lane 2) or presence of 40 nM purified His6-Q1 (lanes 3 to 6), His6-Q2 (lanes 7 to 10) or His6-BzdR (lanes 11 to 14). The ligands shikimate (S) (lanes 4, 8, 12), benzoyl-CoA (BCoA) (lanes 5, 9, 11), and benzoate (Bz) (lanes 6, 10) were added at 1 mM; ATP was added at 4 mM (lane 13). Lanes -, no ligand added. Lane 1, control assay without RNAP.
Figure 5Proposed model for the evolutionary origin of the BzdR protein.
The red arrows represent fusion between a shikimate kinase ancestor and a DNA-binding domain of the HTH-XRE family. This fusion rendered a protein equivalent to the Q1 chimera. A series of mutations led to the loss of enzyme activity (chimera Q1) and finally to increase in the affinity of the protein for the inducer benzoyl-CoA. Sk: shikimate; 3-P-Sk: 3-phosphoshikimate; Bz-CoA: benzoyl-CoA.